Debiopharm Group™ (Debiopharm), Immunexpress Group and Biocartis have announced a world-wide exclusive, royalty-bearing license for the late-stage development and commercialization of SeptiCyte® Triage - a multiplex gene expression assay for use in Emergency and Intensive Care Units (ICUs) or upon hospital admission to diagnose sepsis early, differentiate sepsis from other forms of inflammation, and determine sepsis severity.
Under the terms of the agreement, Debiopharm will fund the validation and U.S. Food and Drug Administration (FDA) clearance of SeptiCyte® Triage and Biocartis will subsequently fund the development and commercialization of the validated SeptiCyte® Triage assay on its fully integrated molecular diagnostics platform.
This platform - which includes an instrument, communication console, and single use, disposable cartridges - can detect and quantify multiple DNA- or RNA-based biomarkers in a wide variety of patient sample types with minimal user intervention in less than 90 minutes.
As part of the agreement, Debiopharm will complete an equity investment in Immunexpress of AUD 2 million.
“The synergy created by this partnership is not only important for the continued development and future availability of SeptiCyte® Triage - but it also exemplifies Immunexpress’ commitment to innovative science and partnerships that improve outcomes for clinicians and patients”, said Dr Roslyn Brandon, President and CEO, Immunexpress.
Dr Brandon continued, “With accuracy significantly better than procalcitonin, bringing SeptiCyte® Triage onto Biocartis’ revolutionary point-of-need multiplex qRT-PCR platform will enable clinicians to more quickly and accurately identify and triage patients suspected of sepsis».
Greg Parekh, Biocartis’ CEO, commented: “Biocartis is striving to bring more effective, individualized treatments within reach of patients through the availability of high quality diagnostics at the point of need. Sepsis is a major cause of death where timely accurate diagnostic information can make a significant difference in medical outcomes”.
“Debiopharm is enthusiastic to join forces with Immunexpress and Biocartis and to take an additional step in our strong commitment to personalized medicine”, said Thierry Mauvernay, Debiopharm’s delegate of the board, who added, “The collaboration opens the door to exploit synergies between the three companies by addressing this life-threatening condition from different perspectives, particularly from a health economics one. Supporting better management of sepsis may ultimately lead to a reduction in mortality, better outcomes and possibly the discovery of new therapies”.